Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 168

Similar articles for PubMed (Select 21889920)


Frequent low expression of chromatin remodeling gene ARID1A in breast cancer and its clinical significance.

Zhang X, Zhang Y, Yang Y, Niu M, Sun S, Ji H, Ma Y, Yao G, Jiang Y, Shan M, Zhang G, Pang D.

Cancer Epidemiol. 2012 Jun;36(3):288-93. doi: 10.1016/j.canep.2011.07.006. Epub 2011 Sep 1.


Promoter hypermethylation of ARID1A gene is responsible for its low mRNA expression in many invasive breast cancers.

Zhang X, Sun Q, Shan M, Niu M, Liu T, Xia B, Liang X, Wei W, Sun S, Zhang Y, Liu XS, Song Q, Yang Y, Ma Y, Liu Y, Yang L, Ren Y, Zhang G, Pang D.

PLoS One. 2013;8(1):e53931. doi: 10.1371/journal.pone.0053931. Epub 2013 Jan 21.


Decreased expression of the ARID1A gene is associated with poor prognosis in primary gastric cancer.

Wang DD, Chen YB, Pan K, Wang W, Chen SP, Chen JG, Zhao JJ, Lv L, Pan QZ, Li YQ, Wang QJ, Huang LX, Ke ML, He J, Xia JC.

PLoS One. 2012;7(7):e40364. doi: 10.1371/journal.pone.0040364. Epub 2012 Jul 13.


Loss of ARID1A/BAF250a expression is linked to tumor progression and adverse prognosis in cervical cancer.

Cho H, Kim JS, Chung H, Perry C, Lee H, Kim JH.

Hum Pathol. 2013 Jul;44(7):1365-74. doi: 10.1016/j.humpath.2012.11.007. Epub 2013 Feb 18.


High levels of γ-glutamyl hydrolase (GGH) are associated with poor prognosis and unfavorable clinical outcomes in invasive breast cancer.

Shubbar E, Helou K, Kovács A, Nemes S, Hajizadeh S, Enerbäck C, Einbeigi Z.

BMC Cancer. 2013 Feb 1;13:47. doi: 10.1186/1471-2407-13-47.


The chromatin remodeling gene ARID1A is a new prognostic marker in clear cell renal cell carcinoma.

Lichner Z, Scorilas A, White NM, Girgis AH, Rotstein L, Wiegand KC, Latif A, Chow C, Huntsman D, Yousef GM.

Am J Pathol. 2013 Apr;182(4):1163-70. doi: 10.1016/j.ajpath.2013.01.007. Epub 2013 Feb 12.


ARID1A: a potential prognostic factor for breast cancer.

Zhao J, Liu C, Zhao Z.

Tumour Biol. 2014 May;35(5):4813-9. doi: 10.1007/s13277-014-1632-7. Epub 2014 Jan 16.


[Expression and clinical significance of LRP16 gene in human breast cancer].

Liao DX, Han WD, Zhao YL, Pu YD, Mu YM, Luo CH, Li XH.

Ai Zheng. 2006 Jul;25(7):866-70. Chinese.


ARID1A/BAF250a as a prognostic marker for gastric carcinoma: a study of 2 cohorts.

Wiegand KC, Sy K, Kalloger SE, Li-Chang H, Woods R, Kumar A, Streutker CJ, Hafezi-Bakhtiari S, Zhou C, Lim HJ, Huntsman DG, Clarke B, Schaeffer DF.

Hum Pathol. 2014 Jun;45(6):1258-68. doi: 10.1016/j.humpath.2014.02.006. Epub 2014 Feb 20.


Down-regulation of CacyBP is associated with poor prognosis and the effects on COX-2 expression in breast cancer.

Nie F, Yu XL, Wang XG, Tang YF, Wang LL, Ma L.

Int J Oncol. 2010 Nov;37(5):1261-9.


Expression pattern of stromal cell-derived factor-1 chemokine in invasive breast cancer is correlated with estrogen receptor status and patient prognosis.

Kobayashi T, Tsuda H, Moriya T, Yamasaki T, Kikuchi R, Ueda S, Omata J, Yamamoto J, Matsubara O.

Breast Cancer Res Treat. 2010 Oct;123(3):733-45. doi: 10.1007/s10549-009-0672-y. Epub 2009 Dec 18.


Reduced expression of the chromatin remodeling gene ARID1A enhances gastric cancer cell migration and invasion via downregulation of E-cadherin transcription.

Yan HB, Wang XF, Zhang Q, Tang ZQ, Jiang YH, Fan HZ, Sun YH, Yang PY, Liu F.

Carcinogenesis. 2014 Apr;35(4):867-76. doi: 10.1093/carcin/bgt398. Epub 2013 Nov 30.


A novel tumor suppressor gene RhoBTB2 (DBC2): frequent loss of expression in sporadic breast cancer.

Mao H, Qu X, Yang Y, Zuo W, Bi Y, Zhou C, Yin H, Deng B, Sun J, Zhang L.

Mol Carcinog. 2010 Mar;49(3):283-9. doi: 10.1002/mc.20598.


A functional proteogenomic analysis of endometrioid and clear cell carcinomas using reverse phase protein array and mutation analysis: protein expression is histotype-specific and loss of ARID1A/BAF250a is associated with AKT phosphorylation.

Wiegand KC, Hennessy BT, Leung S, Wang Y, Ju Z, McGahren M, Kalloger SE, Finlayson S, Stemke-Hale K, Lu Y, Zhang F, Anglesio MS, Gilks B, Mills GB, Huntsman DG, Carey MS.

BMC Cancer. 2014 Feb 22;14:120. doi: 10.1186/1471-2407-14-120.


Disseminated tumor cells in bone marrow assessed by TWIST1, cytokeratin 19, and mammaglobin A mRNA predict clinical outcome in operable breast cancer patients.

Tjensvoll K, Oltedal S, Farmen RK, Shammas FV, Heikkilä R, Kvaløy JT, Gilje B, Smaaland R, Nordgård O.

Clin Breast Cancer. 2010 Oct 1;10(5):378-84. doi: 10.3816/CBC.2010.n.050.


The difference in miR-21 expression levels between invasive and non-invasive breast cancers emphasizes its role in breast cancer invasion.

Petrović N, Mandušić V, Stanojević B, Lukić S, Todorović L, Roganović J, Dimitrijević B.

Med Oncol. 2014 Mar;31(3):867. doi: 10.1007/s12032-014-0867-x. Epub 2014 Feb 2.


High levels of BCOX1 expression are associated with poor prognosis in patients with invasive ductal carcinomas of the breast.

Liu T, Zhang XY, He XH, Geng JS, Liu Y, Kong DJ, Shi QY, Liu F, Wei W, Pang D.

PLoS One. 2014 Jan 28;9(1):e86952. doi: 10.1371/journal.pone.0086952. eCollection 2014.


ARID1A, a factor that promotes formation of SWI/SNF-mediated chromatin remodeling, is a tumor suppressor in gynecologic cancers.

Guan B, Wang TL, Shih IeM.

Cancer Res. 2011 Nov 1;71(21):6718-27. doi: 10.1158/0008-5472.CAN-11-1562. Epub 2011 Sep 7. Erratum in: Cancer Res. 2012 Jun 15;72(12):3116.


Clinical relevance of Ki67 gene expression analysis using formalin-fixed paraffin-embedded breast cancer specimens.

Yamamoto S, Ibusuki M, Yamamoto Y, Fu P, Fujiwara S, Murakami K, Iwase H.

Breast Cancer. 2013 Jul;20(3):262-70. doi: 10.1007/s12282-012-0332-7. Epub 2012 Feb 24.


Role of MRE11 in cell proliferation, tumor invasion, and DNA repair in breast cancer.

Yuan SS, Hou MF, Hsieh YC, Huang CY, Lee YC, Chen YJ, Lo S.

J Natl Cancer Inst. 2012 Oct 3;104(19):1485-502. doi: 10.1093/jnci/djs355. Epub 2012 Aug 22.

Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk